Rathinasabapathy, Anandharajan Rathinasabapathy

List of Publications by Year
in descending order

36 papers	955 citations	12 h-index	22 g-index
37 all docs	37 docs citations	37 times ranked	1695 citing authors

759233
677142

#	Article	IF	Citations
1	Differential serum lipid distribution in IPAH and CHD-PAH patients. Respiratory Medicine, 2022, 191, 106711.	2.9	7
2	Thromboxaneâ€"Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 596-607.	5.6	9
3	KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models. International Journal of Molecular Sciences, 2021, 22, 5014.	4.1	11
4	Prevalence of Schistosoma japonicum-associated Pulmonary Hypertension in China: An Echocardiography-based Assessment. Annals of the American Thoracic Society, 2021, 18, 2095-2098.	3.2	3
5	Overexpression of Msx1 in Mouse Lung Leads to Loss of Pulmonary Vessels Following Vascular Hypoxic Injury. Cells, 2021, 10, 2306.	4.1	0
6	Association of cardiac injury with hypertension in hospitalized patients with COVID-19 in China. Scientific Reports, 2021, 11, 22389.	3.3	4
7	Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2020, 7, 540.	2.6	5
8	A First Report on Mass Cytometry Immunophenotyping of Peripheral Blood Mononuclear Cells in Pulmonary Arterial Hypertension. , 2020, , .		0
9	Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report. BMC Pulmonary Medicine, 2020, 20, 186.	2.0	7
10	DISPARITIES IN HYPERTENSION PREVALENCE, AWARENESS, TREATMENT, CONTROL, AND ASSOCIATED FACTORS BETWEEN TUJIA AND HAN ETHNIC IN SOUTHWEST CHINA. Journal of the American College of Cardiology, 2019, 73, 1859.	2.8	0
11	Loss of KCNK3 in Mice Drives Susceptibility to Inflammatory Pulmonary Arterial Hypertension. , 2019, , .		0
12	Accumulation of Ceramide in Cardiomyocytes with BMPR2 Mutation Decreases Apoptosis by Disrupting Akt/GSK-3b Signaling Pathway. , 2019, , .		0
13	Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model. Stem Cells International, 2019, 2019, 1-11.	2.5	0
14	Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension. Hypertension, 2018, 71, 1156-1163.	2.7	34
15	Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L118-L126.	2.9	74
16	Ubiquitin chains: a new way of screening for regulatory differences in pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-3.	1.7	1
17	The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in Physiology, 2018, 9, 180.	2.8	53
18	rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. Frontiers in Physiology, 2018, 9, 271.	2.8	30

#	Article	IF	Citations
19	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	6.7	183
20	Therapeutic potential of adipose stem cellâ€derived conditioned medium against pulmonary hypertension and lung fibrosis. British Journal of Pharmacology, 2016, 173, 2859-2879.	5.4	44
21	Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 59, 71-77.	3.1	18
22	7A.04. Journal of Hypertension, 2015, 33, e90.	0.5	3
23	PP.21.33. Journal of Hypertension, 2015, 33, e327-e328.	0.5	0
24	Selective activation of angiotensin <scp>AT</scp>₂ receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. British Journal of Pharmacology, 2015, 172, 2219-2231.	5.4	75
25	Adipose Stem Cells attenuates Bleomycin induced Pulmonary Fibrosis. FASEB Journal, 2015, 29, LB750.	0.5	0
26	Diminazene, an ACE2 Activator Modulates Gut Microbiota and Provides Protection Against Pulmonary Hypertension. FASEB Journal, 2015, 29, LB749.	0.5	0
27	A Nonpeptide Angiotensin II Type 2 Receptor Agonist Prevents Pulmonary Fibrosis. FASEB Journal, 2015, 29, LB746.	0.5	0
28	Abstract 028: ACE2 Activator, Diminazene, Rebalances Gut Microbial Dysbiosis and Attenuates Pulmonary Hypertension. Hypertension, 2015, 66, .	2.7	0
29	C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction. , 2015, , .		0
30	Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension. Hypertension, 2014, 64, 1248-1259.	2.7	126
31	Antiâ€oxidative and antiâ€inflammatory role of adipose stem cells in reversing pulmonary hypertension and associated cardiac remodeling (1090.9). FASEB Journal, 2014, 28, 1090.9.	0.5	0
32	Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 648-657.	5.6	150
33	Genetically Engineered Mesenchymal Stem Cells that Overexpress ACE2 or Angiotensinâ€(1â€"7) Show Enhanced Nitricâ€Oxide Production. FASEB Journal, 2013, 27, lb689.	0.5	0
34	18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism: Clinical and Experimental, 2009, 58, 1503-1516.	3.4	3
35	In vitro glucose uptake activity of Aegles marmelos and Syzygium cumini by activation of Glut-4, PI3 kinase and PPARÎ³ in L6 myotubes. Phytomedicine, 2006, 13, 434-441.	5.3	80
36	Upregulation of Glut-4 and PPARÎ³ by an isoflavone from Pterocarpus marsupium on L6 myotubes: a possible mechanism of action. Journal of Ethnopharmacology, 2005, 97, 253-260.	4.1	35